These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 16116470)
21. Impairment of NK cell function by NKG2D modulation in NOD mice. Ogasawara K; Hamerman JA; Hsin H; Chikuma S; Bour-Jordan H; Chen T; Pertel T; Carnaud C; Bluestone JA; Lanier LL Immunity; 2003 Jan; 18(1):41-51. PubMed ID: 12530974 [TBL] [Abstract][Full Text] [Related]
22. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531 [TBL] [Abstract][Full Text] [Related]
23. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Diefenbach A; Hsia JK; Hsiung MY; Raulet DH Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935 [TBL] [Abstract][Full Text] [Related]
24. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803 [TBL] [Abstract][Full Text] [Related]
25. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. Strong RK Mol Immunol; 2002 May; 38(14):1029-37. PubMed ID: 11955595 [TBL] [Abstract][Full Text] [Related]
26. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645 [TBL] [Abstract][Full Text] [Related]
27. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634 [TBL] [Abstract][Full Text] [Related]
28. "Acquired" NKG2D Ligand Stimulates NK Cell-mediated Tumor Immunosurveillance. Wang D; Gu X; Liu X; Liu X; Wang B; Lao F; Fang M J Immunother; 2019; 42(6):189-196. PubMed ID: 31145234 [TBL] [Abstract][Full Text] [Related]
29. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. Elsner L; Muppala V; Gehrmann M; Lozano J; Malzahn D; Bickeböller H; Brunner E; Zientkowska M; Herrmann T; Walter L; Alves F; Multhoff G; Dressel R J Immunol; 2007 Oct; 179(8):5523-33. PubMed ID: 17911639 [TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. Cerboni C; Neri F; Casartelli N; Zingoni A; Cosman D; Rossi P; Santoni A; Doria M J Gen Virol; 2007 Jan; 88(Pt 1):242-250. PubMed ID: 17170457 [TBL] [Abstract][Full Text] [Related]
33. NKG2D-independent suppression of T cell proliferation by H60 and MICA. Kriegeskorte AK; Gebhardt FE; Porcellini S; Schiemann M; Stemberger C; Franz TJ; Huster KM; Carayannopoulos LN; Yokoyama WM; Colonna M; Siccardi AG; Bauer S; Busch DH Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11805-10. PubMed ID: 16091471 [TBL] [Abstract][Full Text] [Related]
34. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. Abdool K; Cretney E; Brooks AD; Kelly JM; Swann J; Shanker A; Bere EW; Yokoyama WM; Ortaldo JR; Smyth MJ; Sayers TJ J Immunol; 2006 Aug; 177(4):2575-83. PubMed ID: 16888019 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663 [TBL] [Abstract][Full Text] [Related]
37. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537 [TBL] [Abstract][Full Text] [Related]
38. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. McCann FE; Eissmann P; Onfelt B; Leung R; Davis DM J Immunol; 2007 Mar; 178(6):3418-26. PubMed ID: 17339436 [TBL] [Abstract][Full Text] [Related]
39. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564 [TBL] [Abstract][Full Text] [Related]
40. NKG2D and cytotoxic effector function in tumor immune surveillance. Hayakawa Y; Smyth MJ Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]